Print Page     Close Window     

SEC Filings

SC 13G
ALTIUM CAPITAL MANAGEMENT LP filed this Form SC 13G on 02/08/2019
Entire Document
 
 

 

CUSIP No. 81577F109   Page 5 of 7

 

Item 1(a).  

Name of Issuer:                                                         

Seelos Therapeutics, Inc (the “Issuer”)

     
     
     
Item 1(b).  

Address of Issuer’s Principal Executive Offices:

300 Park Avenue, 12th Floor

New York, NY 10022

     
     
     
     
Item 2(a).  

Name of Person Filing:

This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP, Altium Capital Management, LP, and Altium Growth GP, LLC. Altium Growth Fund, LP is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, Altium Growth Fund, LP. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, Altium Growth Fund, LP.

 

Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

 

Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

     
     
     
Item 2(b).   Address of Principal Business Office or, if None, Residence:
    The address of the principal business office of each of the reporting persons is 551 Fifth  Ave, FL 19 New York, NY 10176
     
     
     
Item 2(c).   Citizenship:
    See Item 4 on the cover page(s) hereto.
     
     
Item 2(d).   Title of Class of Securities:
    Common Stock
     
     
Item 2(e).   CUSIP Number: 81577F109
     
     
     
 

© Apricus Biosciences, Inc.